$9.350
+0.246 (+2.63%)終値時点
PBYI のニュース
PBYI のイベント
Sees Q3 Royalty Revenue of $2M-$3M
Sees Q3 royalty revenue $2M-$3M, net product revenue $54M-$56M
Sees FY26 Net Revenue at $202M-$206M
Sees FY26 net produce revenue $202M-$206M, sees FY26 royalty revenue $20M-$23M
Puma Reports Q2 Revenue of $56.5M, Up 8% Year-over-Year
Reports Q2 revenue $56.5M vs $52.4M last year. "We are pleased with our commercial execution in the second quarter and the continued increase in year-over-year demand for NERLYNX. We are also pleased with our continued progress across our clinical development programs during the second quarter," said Alan H. Auerbach, Chairman, Chief Executive Officer and President of Puma. "We remain focused on both continuing our commercial execution in the second half of the year as well as with continuing to advance alisertib in the respective ALISCA clinical trials in HER2-negative, hormone receptor-positive metastatic breast cancer and small cell lung cancer."
Puma Biotechnology Sees Q2 Revenue of $52M-$55M
Puma Biotechnology sees Q2 revenue $52M-$55M, one estimate $52M
Puma Reports Q1 Revenue of $44.8M, Raises 2026 Revenue Guidance
Reports Q1 revenue $44.8M vs $42M last year. "We are very pleased that the first quarter of 2026 marked another quarter of year-over-year demand increase resulting in our raising revenue guidance for 2026. According to our current forecasts, FY 2026 will mark our second consecutive year of NERLYNX demand increase year over year," said Alan H. Auerbach, Chairman, Chief Executive Officer, and President of Puma. "We are also pleased with the interim data from ALISCA-Breast1 and ALISCA-Lung1, which appear to demonstrate an increased clinical effect of alisertib in biomarker subgroups where aurora kinase A appears to be playing a role. We look forward to continuing the development of alisertib in ALISCA-Breast1 and ALISCA-Lung1 while carefully managing our resources to achieve positive net income for this year."
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。